Geron Corporation (GERN) on Monday provided financial guidance for 2026, expecting net product revenue for Rytelo in the range of $220 million to $240 million.
The company said its 2026 outlook reflects expected top-line growth alongside a reduction in operating spend year over year.
Total operating expenses are expected in the range of $230 million to $240 million in 2026.
Rytelo is approved in the U.S. for the treatment of lower-risk myelodysplastic syndrome (LR-MDS) with transfusion-dependent anemia. It is also approved in the European Union as a monotherapy for adult patients with transfusion-dependent anemia due to very low, low, or intermediate-risk myelodysplastic syndromes.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.